Valion Bio, Inc. (VBIO) stock
VBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.53+0.02 (+4.05%)
Close on Nov 13, 2026Market cap $2.20MP/E –Yield –
Valion Bio gross margin
Gross margin is gross profit as a percentage of revenue.
Valion Bio's gross margin for the twelve months ending Sep 30, 2025 was -58.1%. For fiscal 2024 it was 0.3%, against 24.4% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0.3% | −24.1 |
| FY2023 | Dec 31, 2023 | 24.4% | +8.2 |
| FY2022 | Dec 31, 2022 | 16.3% | +19.3 |
| FY2021 | Dec 31, 2021 | -3.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2025 | Sep 30, 2025 | -99.3% | −134.2 |
| Q2 FY2025 | Jun 30, 2025 | 62.8% | +41.4 |
| Q1 FY2025 | Mar 31, 2025 | 71.4% | +21.4 |
| Q4 FY2024 | Dec 31, 2024 | -132.8% | −134.2 |
| Q3 FY2024 | Sep 30, 2024 | 34.9% | −3.4 |
| Q2 FY2024 | Jun 30, 2024 | 21.4% | −16.5 |
| Q1 FY2024 | Mar 31, 2024 | 50.0% | +19.9 |
| Q4 FY2023 | Dec 31, 2023 | 1.4% | −9.1 |
| Q3 FY2023 | Sep 30, 2023 | 38.3% | +25.1 |
| Q2 FY2023 | Jun 30, 2023 | 37.9% | +14.2 |
| Q1 FY2023 | Mar 31, 2023 | 30.1% | +13.7 |
| Q4 FY2022 | Dec 31, 2022 | 10.5% | +11.1 |
| Q3 FY2022 | Sep 30, 2022 | 13.2% | +22.6 |
| Q2 FY2022 | Jun 30, 2022 | 23.7% | +36.0 |
| Q1 FY2022 | Mar 31, 2022 | 16.4% | +9.5 |
| Q4 FY2021 | Dec 31, 2021 | -0.5% | – |
| Q3 FY2021 | Sep 30, 2021 | -9.4% | – |
| Q2 FY2021 | Jun 30, 2021 | -12.3% | – |
| Q1 FY2021 | Mar 31, 2021 | 6.8% | – |
See a number that looks wrong?